Download PDFPDF

Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Paucity of evidence guiding patients during deteriorating asthma control
    • Graeme P Currie
    • Other Contributors:
      • Daniel KC Lee, Department of Respiratory Medicine, Ipswich Hospital, Ipswich IP4 5PD.

    Dear Editor,

    The paper by Fitzgerald et al [1] raises important questions as to what patients should be advised to do during periods of less well controlled asthma. In other words, the commonly advised practice of doubling the inhaled corticosteroid dose is not backed up by a wealth of evidence, in turn resulting in an embarassing paucity of clear guidance for patients.

    It has become apparent in the...

    Show More
    Conflict of Interest:
    None declared.